聚乙二醇干扰素α-2a(40KD)治疗儿童慢性乙型肝炎的疗效与安全性:PEG-B-ACTIVE研究
PEG-B-ACTIVE III期研究纳入161例3至<18岁HBeAg阳性免疫活动期慢性乙型肝炎患儿,按2:1随机分为聚乙二醇干扰素α-2a组(A组101例)和无治疗组(B组50例),另10例进展期纤维化/肝硬化患儿入C组接受聚乙二醇干扰素α-2a。治疗48周后随访24周,A组HBeAg血清学转换率、HBsAg清除率、HBV DNA<2,000 IU/mL及不可测比例、ALT复常率均显著高于B组,安全性与成人或丙肝患儿已知特征相当,生长参数变化轻微。
要点
- A组治疗结束后24周HBeAg血清学转换率为25.7%,显著高于B组的6%(P=0.0043)。
- A组HBsAg清除率为8.9%,B组为0%(P=0.03)。
- A组ALT复常率为51.5%,显著高于B组的12%(P<0.001)。
核心结论
- 聚乙二醇干扰素α-2a治疗儿童免疫活动期慢性乙型肝炎有效且耐受良好,HBsAg清除率高于成人。
研究设计与样本
- PEG-B-ACTIVE(NCT01519960)III期研究纳入161例3至<18岁HBeAg阳性免疫活动期无进展期纤维化/肝硬化的慢性乙型肝炎患儿,按2:1随机分为A组(聚乙二醇干扰素α-2a,n=101)和B组(无治疗,n=50)。
- 进展期纤维化患儿10例入C组接受聚乙二醇干扰素α-2a(n=10)。
- 聚乙二醇干扰素α-2a按体表面积分类给药,基于180 μg/1.73 m²,疗程48周。
主要发现
- 治疗结束后24周HBeAg血清学转换率A组25.7% vs B组6%(P=0.0043)。
- HBsAg清除率A组8.9% vs B组0%(P=0.03)。
- HBV DNA<2,000 IU/mL比例A组28.7% vs B组2.0%(P<0.001);HBV DNA不可测比例A组16.8% vs B组2.0%(P=0.0069)。
- ALT复常率A组51.5% vs B组12%(P<0.001)。
- 安全性(包括ALT flares和中性粒细胞减少发生率)与聚乙二醇干扰素α-2a在HBV感染成人或HCV感染儿童中的已知特征相当;治疗期间生长参数变化轻微,与未治疗患者相当;C组安全性和疗效结果与A组一致。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Children with chronic hepatitis B (CHB) represent an area of unmet medical need, attributed to increased lifetime risk of CHB sequelae and limited therapeutic options compared with adult CHB patients. The PEG-B-ACTIVE (NCT01519960) phase III study evaluated peginterferon (PegIFN) alfa-2a treatment in children aged 3 to <18 years with CHB. A total of 161 hepatitis B e antigen (HBeAg)-positive immune-active patients without advanced fibrosis (AF)/cirrhosis were randomized (2:1) to PegIFN alfa-2a (Group A, n = 101) or no treatment (Group B, n = 50); patients with AF were assigned to PegIFN alfa-2a (Group C, n = 10). PegIFN alfa-2a was administered for 48 weeks by body surface area (BSA) category, based on 180 μg/1.73 m2 . HBeAg seroconversion rates at 24 weeks posttreatment were significantly higher in Group A (25.7% vs. 6%; P = 0.0043), as were the rates of hepatitis B surface antigen (HBsAg) clearance (8.9% vs. 0%; P = 0.03), hepatitis B virus (HBV) DNA <2,000 IU/mL (28.7% vs. 2.0%; P < 0.001) or undetectable (16.8% vs. 2.0%; P = 0.0069), and alanine aminotransferase (ALT) normalization (51.5% vs. 12%; P < 0.001). Safety, including incidence of ALT flares and neutropenia, was comparable to the established PegIFN alfa-2a profile in HBV-infected adults or hepatitis C virus-infected children. Changes in growth parameters were minimal during treatment and comparable to those in untreated patients. Safety and efficacy outcomes in Group C were in line with Group A. Conclusion: PegIFN alfa-2a treatment of children in the immune-active phase of CHB was efficacious and well tolerated, and associated with higher incidence of HBsAg clearance than in adults. This represents an important advance to the treatment options for children with CHB.
引用
- Wirth S, Zhang H, Hardikar W, et al. Efficacy and Safety of Peginterferon Alfa-2a (40KD) in Children With Chronic Hepatitis B: The PEG-B-ACTIVE Study. Hepatology. 2018. PMID: 29689122. doi:10.1002/hep.30050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。